BeiGene Begins Commercializing XGEVA® (Denosumab) in China
June 30, 2020 19:30 ET
|
BeiGene, LTD.
BEIJING, China and CAMBRIDGE, Mass., June 30, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
BeiGene Announces Closing of Amgen Global Strategic Oncology Collaboration and Equity Investment
January 02, 2020 08:15 ET
|
BeiGene, LTD.
Amgen Completes Purchase of Approximately $2.8 Billion of BeiGene SharesAnthony C. Hooper, Former Executive Vice President of Global Commercial Operations at Amgen, Joins BeiGene Board of Directors ...
BeiGene Announces Global Strategic Oncology Collaboration with Amgen
October 31, 2019 16:00 ET
|
BeiGene, LTD.
• Companies to Collaborate on the Commercialization of XGEVA® (denosumab), KYPROLIS® (carfilzomib), and BLINCYTO® (blinatumomab) in China • Companies to Jointly Develop 20 Amgen Oncology Pipeline...